stonks4u
Sign up free
ANNX logo

ANNX Annexon, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$5.29
+0.03 (+0.57%)

Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen…

Market Cap: $866.73Mwww.annexonbio.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

104
104
Aug 12Aug 12

Quote

Day Range
$5.08 – $5.34
52-Week Range
$2.03 – $7.18
Volume
$2.99M
Market Cap
$866.73M
50-Day Avg
$5.36
200-Day Avg
$5.24
Prev Close
$5.26
Open
$5.23

Valuation & Ratios

P/E Ratio
-3.75
EPS
$-1.33
P/B Ratio
3.68
P/S Ratio
0.00
Debt/Equity
0.12
Current Ratio
5.68
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-97.7%
Return on Assets
-74.5%
FCF Yield
-24.0%
EV/EBITDA
-3.15

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-206.69M$-1.34
2024$0.00$-138.20M$-1.01
2023$0.00$-134.24M$-1.77
2022$0.00$-141.95M$-2.60
2021$0.00$-130.32M$-3.34

Social Signal Score

55
5d
55
4 mentions
—
30d
55
4 mentions
—
60d
55
4 mentions
—
90d
55
4 mentions
—
news: 4

Earnings

Mon, Nov 9(in 3 months)

Consensus estimate $-0.26 per share

3of 7 quarters beat consensus

Typical surprise -8.8% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, Aug 12$-0.28 vs $-0.24miss
  • Thu, May 7$-0.23 vs $-0.30beat
  • Mon, Mar 30$-0.28 vs $-0.32beat
  • Mon, Nov 10$-0.37 vs $-0.34miss
  • Thu, Aug 14$-0.34 vs $-0.36beat
  • Mon, May 12$-0.37 vs $-0.30miss

Estimates and results for ANNX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

ANNXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (4)

  • Newsseekingalpha.com·3d ago·Positive

    Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript

    View source ↗
  • Newsmarketbeat.com·3d ago·Positive

    Annexon Q2 Earnings Call Highlights Annexon NASDAQ: ANNX said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study's existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the 15-month endpoint while seeking to capture longer-term efficacy data for a potential product label.

    View source ↗
  • Newsglobenewswire.com·3d ago·Negative

    Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026

    View source ↗
  • Newsglobenewswire.com·3d ago·Neutral

    Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the addition of a Month

    View source ↗